Do You Qualify for Blenrep (Belantamab Mafodotin) Coverage by Humana in Ohio? Decision Tree & Next Steps
Answer Box: Quick Eligibility & Action Plan
Blenrep (belantamab mafodotin) was reapproved by the FDA on October 23, 2025 for relapsed/refractory multiple myeloma after ≥2 prior therapies. For Humana coverage in Ohio: (1) Confirm your diagnosis meets FDA criteria, (2) Have your oncologist submit prior authorization with clinical documentation